公开(公告)号：US20240294602A1

公开(公告)日：2024-09-05

申请号：US18647837

申请日：2024-04-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A01N37/46 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/04 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20240100137A1

公开(公告)日：2024-03-28

申请号：US18533733

申请日：2023-12-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Oliver SCHOOR ,  Andrea MAHR

IPC: A61K39/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886

CPC classification number: A61K39/0011 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70503 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/115 ,  C12Q1/6886 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/80 ,  C07K2317/32 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230338489A1

公开(公告)日：2023-10-26

申请号：US18323577

申请日：2023-05-25

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  G16B25/10

CPC classification number: A61K39/0011 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0638 ,  C07K14/71 ,  C07K14/7051 ,  C07K16/2863 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/57484 ,  C07K14/4748 ,  C07K16/30 ,  C07K7/06 ,  C12N5/0636 ,  C07K16/2869 ,  C07K14/721 ,  C12Y207/07031 ,  C12N9/1264 ,  C07K16/38 ,  C07K14/8135 ,  C07K14/47 ,  C12Y116/01 ,  C07K16/40 ,  C12N9/0091 ,  C07K14/705 ,  C07K16/28 ,  G16B25/00 ,  G16B25/10 ,  C07K2319/40 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230312679A1

公开(公告)日：2023-10-05

申请号：US18154091

申请日：2023-01-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  A61K51/10 ,  C12N15/115 ,  G01N33/569 ,  C12P21/02 ,  C07K14/47 ,  C12Q1/6881 ,  C07K14/705 ,  C12N5/0783 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K14/70539 ,  A61K39/0011 ,  A61K51/1027 ,  A61K51/1057 ,  C07K14/4748 ,  C07K14/70503 ,  C07K16/303 ,  C07K16/2833 ,  C12N5/0636 ,  C12N15/115 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/56977 ,  A61K2039/572 ,  A61K2039/5158 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55 ,  C12N2310/16 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241115A1

公开(公告)日：2023-08-03

申请号：US18173177

申请日：2023-02-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241113A1

公开(公告)日：2023-08-03

申请号：US18170698

申请日：2023-02-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230241108A1

公开(公告)日：2023-08-03

申请号：US18164407

申请日：2023-02-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/2818 ,  C07K7/06 ,  C07K14/5434 ,  A61P35/02 ,  A61K39/001102 ,  A61K45/06 ,  C12N5/0636 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  C07K16/244 ,  A61K39/39558 ,  C07K16/2821 ,  A61K38/08 ,  C07K14/4748 ,  A61K2039/5156 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230220045A1

公开(公告)日：2023-07-13

申请号：US18154098

申请日：2023-01-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C07K16/30 ,  C07K16/28 ,  C12P21/02 ,  A61K51/10 ,  A61K39/00 ,  C12Q1/6881 ,  C07K14/47 ,  C12N15/115 ,  C12N5/0783 ,  G01N33/569 ,  C07K14/705

CPC classification number: C07K14/70539 ,  C07K16/303 ,  C07K16/2833 ,  C12P21/02 ,  A61K51/1027 ,  A61K51/1057 ,  A61K39/0011 ,  C12Q1/6881 ,  C07K14/4748 ,  C12N15/115 ,  C12N5/0636 ,  G01N33/56977 ,  C07K14/70503 ,  A61K2039/5158 ,  G01N2333/70539 ,  C12Q2600/156 ,  C12N2310/16 ,  C12Q2600/158 ,  C07K2319/55 ,  C07K2319/30 ,  C07K2319/00 ,  C07K2317/72 ,  C07K2317/73 ,  A61K2039/572

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20230151076A1

公开(公告)日：2023-05-18

申请号：US18057069

申请日：2022-11-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  G01N33/569 ,  A61K38/17 ,  C12Q1/6886 ,  A01N37/46

CPC classification number: C07K14/70539 ,  A61K38/06 ,  C12N9/6491 ,  C12N5/0636 ,  C07K16/30 ,  C07K14/4748 ,  A61K39/0011 ,  C07K16/2833 ,  A61K45/06 ,  C07K14/001 ,  C07K7/06 ,  C07K7/02 ,  G01N33/505 ,  G01N33/566 ,  G01N33/5088 ,  A61K39/0005 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0638 ,  A61K38/08 ,  C07K14/7051 ,  G01N33/56972 ,  C07K14/4702 ,  A61K38/1774 ,  C12Q1/6886 ,  G01N33/56977 ,  A01N37/46 ,  C07K2317/34 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/7051 ,  A61K2039/54 ,  G01N2333/70539 ,  C07K2317/31 ,  C07K2317/24 ,  G01N2333/70503 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2502/11 ,  A61K2039/572 ,  G01N2333/47 ,  C12N2501/998 ,  C12Y304/24 ,  A61K2039/57 ,  A61K2039/585 ,  A61K38/00

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20230148369A1

公开(公告)日：2023-05-11

申请号：US17820821

申请日：2022-08-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Toni WEINSCHENK ,  Harpreet SINGH

IPC: C07K14/47 ,  A61P35/00 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/10 ,  C12N15/115 ,  G01N33/574 ,  A61K35/17 ,  C07K7/06 ,  C07K14/54

CPC classification number: C07K14/4748 ,  A61P35/00 ,  A61K39/001102 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2818 ,  C07K16/30 ,  C12N5/0638 ,  C12N15/1062 ,  C12N15/115 ,  G01N33/57492 ,  A61K35/17 ,  C07K7/06 ,  C07K14/5434 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2319/00 ,  C12N2501/50 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.